Selective beta(1)-blockade improves cardiac bioenergetics and function and decreases neuroendocrine activation in rats during early postinfarct remodeling.

In spite of the solid evidence that beta-blockade reduces mortality and morbidity in congestive heart failure (CHF) this therapy continues to be underused in clinical praxis. The reason for this may lie in scarcity of knowledge about the mechanisms of beta-blockade action. The major aim of this study was to investigate in vivo whether selective beta(1)-blockade may improve cardiac energy metabolism in rats with myocardial infarction in early postinfarct remodeling phase. Myocardial infarction (MI) was induced in male Sprague-Dawley rats by ligation of the left coronary artery. Two different groups of rats were studied, rats with MI treated with metoprolol (5 mg/kg/h; n = 9) and rats with MI saline treated (n = 9). The treatment with metoprolol was given by subcutaneously implanted minipumps and was initiated at 3 days postinfarct and during the period of 4 weeks. All rats were investigated with noninvasive methods (31)P magnetic resonance spectroscopy (MRS) and transthoracic echocardiography 3 days after induction of MI and 4 weeks later. Phosphocreatine/ATP ratio was normalized after the treatment with metoprolol while it was 50% lower in the saline group (p < 0.001). In the metoprolol group stroke volume and ejection fraction increased while deceleration time of mitral early filling was longer (all p < 0.05). Left ventricular weight as well as volumes and dimensions were similar between the groups. Plasma levels of noradrenaline (p = 0.058), adrenaline (p < 0.01) and brain natriuretic peptide (p = 0.09) were lower in the metoprolol group. Selective beta(1)-blockade with high dose of metoprolol initiated in the early postinfarct phase improves myocardial energy metabolism and function and prevents overactivation of sympathetic system. The beneficial effect on myocardial bioenergetics may be an important mode of action of beta-blockers which contributes to the clinical benefits of the therapy in CHF.

[1]  G Cooper,et al.  Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. , 2000, Circulation.

[2]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[3]  S. Neubauer,et al.  Effects of ACE inhibition and β-receptor blockade on energy metabolism in rats postmyocardial infarction. , 1999, American journal of physiology. Heart and circulatory physiology.

[4]  S. Vatner,et al.  Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. , 1999, Circulation.

[5]  S. Neubauer,et al.  Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. , 1999, Circulation.

[6]  E. Bollano,et al.  Bioenergetic, functional and morphological consequences of postinfarct cardiac remodeling in the rat. , 1999, Journal of molecular and cellular cardiology.

[7]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[8]  A. Matsumori,et al.  Cellular and molecular remodeling in a heart failure model treated with the β-blocker carteolol. , 1999, American journal of physiology. Heart and circulatory physiology.

[9]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[10]  M. Bristow,et al.  The role of third‐generation beta‐blocking agents in chronic heart failure , 1998, Clinical cardiology.

[11]  H. Sabbah,et al.  Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. , 1998, Journal of cardiac failure.

[12]  M. Packer.  Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. , 1997, The American journal of cardiology.

[13]  S. Neubauer,et al.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. , 1997, Circulation.

[14]  N. Dhalla,et al.  Differential changes in sympathetic activity in left and right ventricles in congestive heart failure after myocardial infarction. , 1997, American heart journal.

[15]  W. Abraham,et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. , 1996, Circulation.

[16]  M. Yokoyama,et al.  Negative chronotropic effect of beta-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work. , 1996, Circulation.

[17]  J. Ingwall,et al.  Energetic basis for reduced contractile reserve in isolated rat hearts. , 1996, The American journal of physiology.

[18]  S. Neubauer,et al.  Long-term beta-blocker treatment prevents chronic creatine kinase and lactate dehydrogenase system changes in rat hearts after myocardial infarction. , 1996, Journal of the American College of Cardiology.

[19]  A. Carlsson,et al.  In vivo activity of tyrosine hydroxylase in rat adrenal glands following administration of quinpirole and dopamine. , 1995, European journal of pharmacology.

[20]  P. Grayburn,et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. , 1995, Journal of the American College of Cardiology.

[21]  Katz Am.  Metabolism of the failing heart. , 1993 .

[22]  S. Gubin,et al.  Non-invasive assessment of ventricular damage in rats with myocardial infarction. , 1993, Cardiovascular research.

[23]  M. Lesch,et al.  Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. , 1992, Journal of molecular and cellular cardiology.

[24]  S. Kostin,et al.  Myocardial alterations induced by prolonged noradrenaline administration in various doses , 1992, Clinical cardiology.

[25]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[26]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[27]  G. Radda,et al.  Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy , 1991, The Lancet.

[28]  T. Hedner,et al.  Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. , 1991, Journal of the American College of Cardiology.

[29]  J. E. Skinner,et al.  Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. , 1990, Circulation research.

[30]  P. Anversa,et al.  Left ventricular failure induced by myocardial infarction. II. Tissue morphometry. , 1985, The American journal of physiology.

[31]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[32]  E Jüngling,et al.  Free energy change of ATP-hydrolysis: a causal factor of early hypoxic failure of the myocardium? , 1982, Journal of molecular and cellular cardiology.

[33]  J. Kjekshus,et al.  The Effect of Free Fatty Acids on Myocardial Oxygen Consumption During Atrial Pacing and Catecholamine Infusion in Man , 1978, Circulation.

[34]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[35]  A. Katz.  Biochemical “Defect’ in the Hypertrophied and Failing Heart: Deleterious or Compensatory? , 1973, Circulation.

[36]  J. Ingwall.  Is cardiac failure a consequence of decreased energy reserve , 1993 .